Interleukin-6 is a potential biomarker for severe pandemic H1N1 influenza a infection

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Paquette, Stéphane G ^a,b   Banner, David ^a   Zhao, Zhen ^c   Fang, Yuan ^a,b   Huang, Stephen S H ^a,b   León, Alberto J ^a,c   Ng, Derek C K ^a   Almansa, Raquel ^d   Martin Loeches, Ignacio ^e   Ramirez, Paula ^f   Socias, Lorenzo ^g   Loza, Ana ^h   Blanco, Jesus ⁱ   Sansonetti, Paola ^j   Rello, Jordi ^k   Andaluz, David ⁱ   Shum, Bianche ^l   Rubino, Salvatore ^m   de Lejarazu, Raul Ortiz ^d   Tran, Dat ⁿ   Delogu, Giovanni ^j   Fadda, Giovanni ^j   Krajden, Sigmund ^l   Rubin, Barry B ^a   Bermejo Martin, Jesús F ^d   Kelvin, Alyson A ^o   Kelvin, David J ^a,b,c,m,o   more..

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^d HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^e Sabadell University Hospital   (Spain)

^f HOSPITAL UNIVERSITARIO LA FE   (Spain)

^g HOSPITAL SON LLÀTZER   (Spain)

^h HOSPITAL UNIVERSITARIO DE VALME   (Spain)

ⁱ Servicio de Programas de Salud y Prevención de la Dirección Técnica de Recursos Humanos y Gestión de Centros Gerencia de Servicios Sociales   (Spain)

^j CATHOLIC UNIVERSITY   (Italy)

^k HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^l ST JOSEPH S HEALTH CENTRE   (Canada)

^m UNIVERSITY OF SASSARI   (Italy)

ⁿ HOSPITAL FOR SICK CHILDREN   (Canada)

^o Immune Diagnostics and Research   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 6;

2009 H1N1 INFLUENZA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EXPERIMENTAL INFECTION; FATALITY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INTENSIVE CARE; NONHUMAN; PROTEIN BLOOD LEVEL; SURVIVAL; VIRUS LOAD; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; C57BL MOUSE; IMMUNOLOGY; INFLUENZA VIRUS A H1N1; MOUSE; ORTHOMYXOVIRUS INFECTION; PANDEMIC; PATHOGENICITY;

MUS;

ANIMALS; BIOLOGICAL MARKERS; FEMALE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INTERLEUKIN-6; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE INFECTIONS; PANDEMICS; VIRAL LOAD;

EID: 84861853797     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038214     Document Type: Article

References (43)

1. Steinhauer DA, Skehel JJ, (2002) Genetics of influenza viruses. Annu Rev Genet 36: 305-332.
2. Perez-Padilla R, Rosa-Zamboni D, Ponce dL, Hernandez M, Quinones-Falconi F, et al. (2009) Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med 361: 680-689.
3. Kmietowicz Z, (2010) WHO declares that H1N1 pandemic is over. BMJ 341: c4393.
4. Gilsdorf A, Poggensee G, Working Group Pandemic Influenza A(H1N1)v (2009) Influenza A(H1N1)v in Germany: the first 10,000 cases. Euro Surveill 14 pii.
5. Nicoll A, Coulombier D, (2009) Europe's initial experience with pandemic (H1N1) 2009- mitigation and delaying policies and practices. Euro Surveill 14 pii.
6. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza, Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, et al. (2010) Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 362: 1708-1719.
7. Health Protection Agency, Health Protection Scotland, National Public Health Service for Wales, HPA Northern Ireland Swine Influenza Investigation Teams (2009) Epidemiology of new influenza A (H1N1) virus infection, United Kingdom, April-June 2009. Euro Surveill 14 pii.
8. Centers for Disease Control and Prevention (CDC) (2009) Intensive-care patients with severe novel influenza A (H1N1) virus infection- Michigan, June 2009. MMWR Morb Mortal Wkly Rep 58: 749-752.
9. Kumar AM, Zarychanski RM, Pinto RP, Cook DJM, Marshall JM, et al. (2009) Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 302: 1872-1879.
10. Uyeki TMM, Sharma AMD, Branda JAM, (2009) Case records of the Massachusetts General Hospital. Case 40-2009: A 29-year-old man with fever and respiratory failure. N Engl J Med 361: 2558-2569.
11. Ryan GB, Majno G, (1977) Acute inflammation. A review. Am J Pathol 86: 183-276.
12. Rouse BT, Sehrawat S, (2010) Immunity and immunopathology to viruses: what decides the outcome? Nat Rev Immunol 10: 514-526.
13. Feghali CA, Wright TM, (1997) Cytokines in acute and chronic inflammation. Front Biosci 2: d12-d26.
14. Gabay C, Kushner I, (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340: 448-454.
15. Damas P, Ledoux D, Nys M, Vrindts Y, de Groote D, et al. (1992) Cytokine serum level during severe sepsis in human- IL-6 as a marker of severity. Ann Surg 215: 356-362.
16. Zhang Y, Li J, Zhan Y, Wu L, Yu X, et al. (2004) Analysis of serum cytokines in patients with severe acute respiratory syndrome. Infect Immun 72: 4410-4415.
17. Huang KJ, Su IJ, Theron M, Wu YC, Lai SK, et al. (2005) An interferon related cytokine storm in SARS patients. J Med Virol 75: 185-194.
18. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, et al. (2006) Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 12: 1203-1207.
19. Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, et al. (1998) IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 101: 311-320.
20. Lin WC, Lin CF, Chen CL, Chen CW, Lin YS, (2010) Prediction of outcome in patients with acute respiratory distress syndrome by bronchoalveolar lavage inflammatory mediators. Exp Biol Med 235: 57-65.
21. Headley AS, Tolley E, Meduri GU, (1997) Infections and the inflammatory response in acute respiratory distress syndrome. Chest 111: 1306-1321.
22. Skoner DP, Gentile DA, Patel A, Doyle WJ, (1999) Evidence for cytokine mediation of disease expression in adults experimentally infected with influenza A virus. J Infect Dis 180: 10-14.
23. Gentile D, Doyle W, Whiteside T, Fireman P, Hayden FG, et al. (1998) Increased interleukin-6 levels in nasal lavage samples following experimental influenza A virus infection. Clin Diagn Lab Immunol 5: 604-608.
24. Fritz RS, Hayden FG, Calfee DP, Cass LM, Peng AW, et al. (1999) Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. J Infect Dis 180: 586-593.
25. Bermejo-Martin JF, Ortiz dL, Pumarola T, Rello J, Almansa R, et al. (2009) Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Crit Care 13: R201.
26. Otte A, Sauter M, Alleva L, Baumgarte S, Klingel K, et al. (2011) Differential host determinants contribute to the pathogenesis of 2009 pandemic H1N1 and human H5N1 influenza A viruses in experimental mouse models. Am J Pathol 179: 230-239.
27. Huang DW, Sherman BT, Lempicki RA, (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37: 1-13.
28. Huang D, Sherman B, Lempicki R, (2008) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
29. Ferrara JL, (1993) Cytokine dysregulation as a mechanism of graft versus host disease. Curr Opin Immunol 5: 794-799.
30. Peiris JSM, Yuen KY, Osterhaus ADME, Stöhr K, (2003) The severe acute respiratory syndrome. N Engl J Med 349: 2431-2441.
31. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza, Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, et al. (2008) Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 358: 261-273.
32. Cameron MJ, Bermejo-Martin JF, Danesh A, Muller MP, Kelvin DJ, (2008) Human immunopathogenesis of severe acute respiratory syndrome (SARS). Virus Res 133: 13-19.
33. Chan MCW, Cheung CY, Chui WH, Tsao SW, Nicholls JM, et al. (2005) Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir Res 6: 135.
34. Arcaroli J, Fessler MD, Abraham E, (2005) Genetic polymorphisms and sepsis. Shock 24: 300-312.
35. Srivastava B, Blazejewska P, Heßmann M, Bruder D, Geffers R, et al. (2009) Host genetic background strongly influences the response to influenza A virus infections. PLoS ONE 4: e4857.
36. Boon AC, deBeauchamp J, Hollman A, Luke J, Kotb M, et al. (2009) Host genetic variation affects resistance to infection with a highly pathogenic H5N1 influenza A virus in mice. J Virol 83: 10417-10426.
37. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, et al. (1994) Impaired immune and acute-phase responses in interleukin-6 deficient mice. Nature 368: 339-342.
38. Saunders BM, Frank AA, Orme IM, Cooper AM, (2000) Interleukin-6 induces early gamma interferon production in the infected lung but is not required for generation of specific immunity to Mycobacterium tuberculosis infection. Infect Immun. 68: 3322-3326.
39. Ladel CH, Blum C, Dreher A, Reifenberg K, Kopf M, et al. (1997) Lethal tuberculosis in interleukin-6 deficient mutant mice. Infect Immun. 65: 4843-4849.
40. Leon LR, White AA, Kluger MJ, (1998) Role of IL-6 and TNF in thermoregulation and survival during sepsis in mice. Am J Physiol 275: R269-R277.
41. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW, (1994) Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 83: 113-118.
42. Theoharides TC, Boucher W, Spear K, (2002) Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol 128: 344-350.
43. Bland JM, Altman DG, (2004) The logrank test. BMJ 328: 1073.